New drug cocktail aims to wipe out breast cancer before surgery
NCT ID NCT05558722
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding an oral targeted drug called anlotinib to standard chemotherapy can better clear cancer from the breast and lymph nodes before surgery in people with early-stage HER2-negative breast cancer. The study enrolled 31 high-risk patients. The main goal is to see how many achieve a complete response, meaning no cancer remains in the removed tissue.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Anlotinib (a targeted drug that blocks blood vessel growth) plus chemotherapy (albumin-bound paclitaxel, pirarubicin, cyclophosphamide)
- What this could lead to
- If successful, this combination could increase the chance of eliminating all cancer before surgery, potentially improving long-term outcomes for high-risk HER2-negative breast cancer patients.
- What could go wrong
- This is a small, early-phase study with only 31 participants and no comparison group. The added drug may cause more side effects, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER STAGE II are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Xijing Hospital Affiliated to Air Force Military Medical University
Xi'an, Shannxi Province, 710032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug cross the Blood-Brain barrier to attack breast cancer metastases?
- Heating up tumors: could thermal therapy boost immune attack on breast cancer?
- Could a diabetes drug slow breast cancer growth?
- Immune-Boosting cocktail aims to tackle Hard-to-Treat breast cancer
- Old arthritis drug takes on tough cancers in early trial
- New pill shows promise in shrinking Hard-to-Treat breast tumors